Piper Sandler turns positive on CAPR ahead of FDA DMD decision
Piper Sandler turned positive on Capricor Therapeutics (CAPR), saying potential upside from an FDA approval of its Duchenne muscular dystrophy treatment outweighs downside risk.
Capricor Therapeutics (CAPR) drew attention on Tuesday after Piper Sandler turned positive on the biotech company, saying the possible upside from U.S. Food and Drug Administration approval of its Duchenne muscular dystrophy (DMD) treatment now outweighs the downside risk.